A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection (clinicaltrials.gov) - Jul 30, 2025 - P2 | N=102 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial primary completion date: Jul 2025 ➔ Aug 2024
Trial primary completion date • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Transplantation
|